category,datetime,headline,id,image,related,source,summary,url
company,1769296170,Genmab (CPSE:GMAB) Valuation Check After Epcoritamab Trial Update And DARZALEX Royalty Momentum,138248945,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,JNJ,Yahoo,"What Genmabâ€™s latest trial data and royalty update mean for shareholders Genmab (CPSE:GMAB) has drawn fresh attention after releasing Phase 3 EPCORE DLBCL-1 topline data for epcoritamab and reporting 2025 worldwide DARZALEX net trade sales of US$14.35b under its Johnson & Johnson license. The twin updates matter because they touch both sides of the Genmab story: current royalty cash flows from partnered drugs, and the longer term value investors may see in its late stage oncology...",https://finnhub.io/api/news?id=aaff082ce48186ed8149486feb771097be08d4427ec9d0e282866b27216d5b71
